Welcome to our dedicated page for Pacific Software news (Ticker: PFSF), a resource for investors and traders seeking the latest updates and insights on Pacific Software stock.
Pacific Software Inc. reports company developments tied to its completed acquisition of PurMinds NeuroPharma, an OTC-quoted public-company platform focused on precision neuromedicine. News coverage centers on material agreements, capital-structure updates, and product-development themes involving neurological and psychiatric disorders, point-of-care diagnostic solutions, clinical biomarker validation, and therapeutics designed around neuroplasticity and neuroinflammation.
Company announcements also document earlier activity in science-based skin care, wound-healing technology, and memory-health products, including Dermatrix, peptide IDE inhibitor licensing, and the SuppleMEM AD and A.L.Z. Defense supplement brands.
PurMinds Enterprises (OTC:PFSF) filed fiscal 2026 Q2 financials for the quarter ended March 31, 2026 and is executing a PCAOB audit to support an OTCQB/OTCQX uplisting.
The company reported zero revenue, higher operating expenses, a larger net loss, major balance sheet cleanup, and over $2.25 million in private capital raised or committed.
PurMinds Enterprises (OTC:PFSF), a clinical-stage neuroscience company, appointed Angelo Pizzuto as CFO, COO, Secretary and Treasurer, effective immediately, succeeding James DiPrima.
Pizzuto will lead a PCAOB audit over the next two to three months, oversee commercialization of high-value opportunities, and support capital-raising initiatives, including Regulation S and D private placements.
Pacific Software (OTC: PFSF) completed a change of control and Reverse Takeover with PurMinds Holdings effective November 3, 2025, and has rebranded to PurMinds Enterprises. The company confirmed occupancy of a 20,477 sq. ft. cGMP-ready pharmaceutical R&D and production facility on January 12, 2026. Management is finalizing a post-RTO capital structure reflecting a 90/10 equity split and issuing common shares to PurMinds shareholders, while resolving legacy transfer agent instructions. The firm filed a FY 2025 Form 10-K (pre-RTO basis) and expects the Dec 31, 2025 10-Q (due Feb 14, 2026) to be the first consolidated filing. The company has started engaging a PCAOB audit firm as a step toward an OTCQX uplisting targeted in H1 2026.
Pacific Software (OTC: PFSF) announced on Nov 11, 2025 the closing of its acquisition of 10763942 Canada Inc. (dba PurMinds NeuroPharma), with PurMinds management assuming leadership roles and a potential corporate name change pending FINRA approval.
PurMinds unveiled an exclusive global partnership with SpectroChip to integrate PurMinds' precision neuromedicine biomarker work with SpectroChip's photonic chip POCT diagnostic platform. The companies said this creates a new revenue pathway with near-term revenue expected in 2026, and aims to support PurMinds' clinical programs with improved patient stratification and longitudinal data collection.
Pacific Software Inc. (OTC:PFSF) has appointed Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA). Dr. Schiestl, a distinguished scientist with over 200 peer-reviewed publications and 16 patents, brings extensive expertise in molecular toxicology, cancer prevention, and genomics. His research focuses on genetic stability and strategies to prevent genetic diseases and cancer, aligning with Pacific Software's mission to develop innovative skincare products and science-based dietary supplements.
Dr. Schiestl's background includes positions at Harvard School of Public Health and UCLA, where he is currently Professor Emeritus. His work on oxidative stress and its health impacts is particularly relevant to Pacific Software's objectives. CEO Harrysen Mittler expressed enthusiasm about Dr. Schiestl's potential contributions to advancing the company's cosmeceutical technology and supplement offerings.
Pacific Software announced the acquisition of a dietary supplement designed to support brain health and memory, marketed as SuppleMEM AD™ and A.L.Z. Defense™.
The formula, tested by leading Alzheimer's researchers, has been sold for over 8 years. The company is obtaining quotes to manufacture this product in the USA and Mexico, targeting distribution in the third quarter of 2024.
This acquisition aligns with Pacific's strategy to diversify into health and skin care products. The core formula, a blend of natural ingredients, has shown positive results in NIH-funded studies at UC Irvine and the University of Kentucky.
The company expects revenue from retail and wholesale channels. Dr. Leissring resigned as president on June 18, 2024.
Pacific Software announced its acquisition of a science-based dietary supplement focused on brain health and memory function, sold under the brand names SuppleMEM AD™ and A.L.Z. Defense™. This acquisition marks Pacific's expansion beyond its previous focus on skin care and wound healing. CEO Harrysen Mittler stated the product has been profitable for over 8 years, and studies funded by the NIH at the University of California, Irvine, and the University of Kentucky have validated its effectiveness. Pacific's President, Dr. Malcolm Leissring, emphasized that proceeds will support the AD Foundation's Alzheimer’s prevention initiatives.
Pacific Software has secured an exclusive licensing agreement with the University of California to develop, manufacture, and commercialize innovative peptide inhibitors of insulin-degrading enzyme (IDE) for skincare and wound healing applications.
The technology, developed with over $6 million in research funding, will be spearheaded by Dr. Malcolm A. Leissring, who will become the Chief Science Officer of Pacific.
The IDE inhibitors, marketed as Dermatrix™, have shown significant capabilities in boosting collagen production, making them revolutionary for both wound healing and cosmetics. The agreement, effective as of March 5, 2024, also makes UC Regents an equity partner in Pacific.
Pacific Software Inc. (PFSF) announced the acquisition of certain assets from Dreamaderm Inc., including a patented cosmeceutical technology called Dermatrix. Dermatrix boosts collagen production by preserving insulin in the skin, offering a wide range of dermatological applications. The technology was developed by Dr. Malcolm A. Leissring and has the potential to revolutionize the cosmetics and skin care industry.
Pacific Software, Inc. (OTCPINK:PFSF) has issued a letter to shareholders highlighting its achievements and future plans. In 2021, the company undertook significant restructuring and made strides in development with multiple joint ventures and acquisitions. Key successes include launching partnerships with Lincoln Clark and Raffaele Gallo, along with a 51% acquisition of a World of Beer tavern. Looking ahead, the company anticipates several new restaurant openings and a rebranding to align with its growth strategy.